Nycomed seeks bidders for potential $13B sale

Swiss drugmaker Nycomed has hired Goldman Sachs to scout for buyers up for a $13.5 billion deal. Options include licensing Nycomed's experimental lung-disease drug, an IPO, or an outright sale of the entire company. The drugmaker's large business in Eastern Europe and Russia could make it attractive to Big Pharmas looking to grow in emerging markets. Report | Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.